Neumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026
Rhea-AI Summary
Neumora Therapeutics (Nasdaq: NMRA) will report fourth quarter and full year 2025 financial results on Monday, March 30, 2026 and will host a conference call and live webcast at 8:00 a.m. ET.
According to Neumora Therapeutics, the live webcast will be available on the company website and a replay will be archived for up to 30 days. Participants are advised to register at least 10 minutes before the call.
Positive
- None.
Negative
- None.
News Market Reaction – NMRA
In the Mar 16 session, NMRA declined 4.33%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 04 | Conference participation | Neutral | -1.0% | Announcement of participation in Guggenheim Emerging Outlook: Biotech Summit 2026. |
| Jan 05 | Pipeline strategy update | Positive | -1.5% | Outlined 2026 pipeline strategy and multiple anticipated clinical readouts. |
| Jan 05 | Clinical data update | Positive | -1.5% | Reported positive Phase 1b signal-seeking results for NMRA-511 in AD agitation. |
| Nov 06 | Quarterly earnings | Positive | -1.5% | Reported Q3 2025 results, strong cash position, and extended funding runway. |
| Nov 03 | Conference participation | Neutral | -0.3% | Planned participation in two November 2025 healthcare investor conferences. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows multiple positive pipeline and earnings-related updates followed by modestly negative next-day price reactions, suggesting a pattern of weak price follow-through on favorable news.
Over the last few months, Neumora reported several pipeline and financial milestones. On Nov 6, 2025, it posted Q3 2025 results with $171.5M in cash and funding expected into 2027, plus a $40M non-dilutive draw, yet shares fell modestly. Positive Phase 1b data for NMRA-511 on Jan 5, 2026 and a 2026 pipeline strategy update the same day also saw mild negative reactions. Conference participation announcements in November 2025 and February 2026 similarly coincided with small declines, framing today’s earnings date notice within a pattern of cautious trading around company news.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WATERTOWN, Mass., March 16, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that it will host a conference call and live webcast at 8:00 a.m. ET on Monday, March 30, 2026, to report its fourth quarter and full year 2025 financial results and provide a business update.
A live webcast of the event will be available on the events and presentations section of the Company’s website at www.neumoratx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to joining the call.
About Neumora
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the greatest medical challenges of our generation by taking a fundamentally different approach to the way treatments for brain diseases are developed. Our therapeutic pipeline currently consists of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases. Neumora’s mission is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients.
Neumora Contact:
Helen Rubinstein
617-402-5700
Helen.Rubinstein@neumoratx.com
